Innoviva
INVA NASDAQ
Medicare add-on payments
- New
- 0
- Continued
- 2
- Lost
- 1
| Status | Technology | Max add-on payment | Implied cost per case |
|---|---|---|---|
| Continued | ZEVTERA (ceftobiprole medocaril); ABSSSI and CABP indications | $5,288 | $7,050 |
| Continued | ZEVTERA (ceftobiprole medocaril); SAB indication | $16,215 | $21,620 |
| Lost | XACDURO (sulbactam/durlobactam) | $13,680prior-year maximum | $18,240 |
FDA device recalls, last 36 months
FDA data as of . Source: openFDA. FDA data may be out of date.
MediDash tracks device recalls only. No device recalls are matched to this company.